Immunotherapy of murine bladder cancer by irradiated tumor vaccine

Journal Article · Tue Jan 01 00:00:00 EST 1991 · Journal of Urology; (USA)

OSTI ID:6037382

Lamm, D L; Riggs, D R; DeHaven, J I; Bryner, R W ^[1]

---

1. West Virginia Univ. School of Medicine, Morgantown (USA)

This investigation explored the efficacy of irradiated autologous mouse bladder tumor (Ir-MBT2) as an active specific immunotherapeutic agent and as adjuvant therapy with Bacillus Calmette-Guerin (BCG) against a subcutaneously transplanted murine bladder tumor. Tumor incidence was significantly reduced in groups receiving BCG (27%, p less than 0.005) or Ir-MBT2 with BCG (53%, p less than 0.025), compared to control (93%). Survival was significantly improved in groups treated with BCG (100%, p less than 0.005), 10(5) Ir-MBT2 with BCG (53%, p less than 0.01), or 10(7) Ir-MBT2 with BCG (47%, p less than 0.025) compared with control (13%). Surprisingly, Ir-MBT2 consistently reduced the efficacy of BCG alone. Ir-MBT2 alone (10(7)) appeared to enhance tumor growth. Autologous irradiated bladder tumor vaccine, alone or in combination with BCG, displayed no immunotherapeutic advantage. The use of irradiated tumor cell vaccine for bladder cancer therapy may reduce the results achievable with BCG alone.

• OSTI ID: 6037382
• Journal Information: Journal of Urology; (USA), Vol. 145:1; ISSN 0022-5347
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BLADDER
EXPERIMENTAL NEOPLASMS
RADIOIMMUNOTHERAPY
MICE
SURVIVAL TIME
ANIMALS
BODY
IMMUNOLOGY
IMMUNOTHERAPY
MAMMALS
MEDICINE
NUCLEAR MEDICINE
ORGANS
RADIOIMMUNOLOGY
RADIOLOGY
RADIOTHERAPY
RODENTS
THERAPY
URINARY TRACT
VERTEBRATES
550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)